294 related articles for article (PubMed ID: 3524789)
1. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the treatment of acute myeloid leukemia in children. Experience of the Argentinian Group of Acute Leukemia Treatment and the Latin American Group of Malignant Hemopathies Treatment 1967-1987].
Freigeiro D; Scaglione C; Santarelli MT; Sackmann Muriel F; Jiménez E; Pavlovsky S; Bustelo P; Richard L; Kohan R; Kvicala R
Sangre (Barc); 1989 Jun; 34(3):221-8. PubMed ID: 2669186
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
7. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
[TBL] [Abstract][Full Text] [Related]
8. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.
Morrison FS; Kopecky KJ; Head DR; Athens JW; Balcerzak SP; Gumbart C; Dabich L; Costanzi JJ; Coltman CA; Saiki JH
Leukemia; 1992 Jul; 6(7):708-14. PubMed ID: 1625490
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
10. Progress in acute myelogenous leukemia.
Gale RP
Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
[TBL] [Abstract][Full Text] [Related]
11. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A
J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717
[TBL] [Abstract][Full Text] [Related]
12. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
Wiernik PH; Glidewell OJ; Hoagland HC; Brunner KW; Spurr CL; Cuttner J; Silver RT; Carey RW; DelDuca V; Kung FH; Holland JF
Med Pediatr Oncol; 1979; 6(3):261-77. PubMed ID: 381887
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
Ohno R; Kobayashi T; Tanimoto M; Hiraoka A; Imai K; Asou N; Tomonaga M; Tsubaki K; Takahashi I; Kodera Y
Cancer; 1993 Jun; 71(12):3888-95. PubMed ID: 8508355
[TBL] [Abstract][Full Text] [Related]
14. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Urbanitz D; Pielken HJ; Koch P; Büchner T; Hiddemann W; Heinecke A; Wendt F; Maschmeier G; van de Loo J
Onkologie; 1985 Jun; 8(3):157-9. PubMed ID: 3895098
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with Corynebacterium parvum in acute myelocytic leukemia.
Eppinger-Helft M; Pavlovsky S; Hidalgo G; Muriel FS; Suárez A; Garay G; Russo C; Santos M; Macchi A; Lein J
Cancer; 1980 Jan; 45(2):280-4. PubMed ID: 6985835
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Urbanitz D; Büchner T; Pielken H; Koch P; Ludwig WD; Maschmeier G; Heinecke A; van de Loo J
Haematol Blood Transfus; 1987; 30():64-8. PubMed ID: 3305224
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
[TBL] [Abstract][Full Text] [Related]
20. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
